Drug intelligence / Profile preview

FibroCell-001

Development stage: Preclinical
Lead developer: Shanghai Ninth People's Hospital
Modality: Cell Therapies
Administration: Injection

Overview

FibroCell-001 is an allogeneic human fibroblast cell therapy administered via injection. It is currently being investigated for the treatment of intervertebral disc degeneration, with clinical studies exploring different dose groups (low, middle, and high dose). The therapy aims to promote tissue repair and regeneration within the degenerated intervertebral disc.

Beyond the preview

Go deeper on FibroCell-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FibroCell-001.

Explore the full profile